|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.4 SEK | +7.69% |
|
+8.70% | -19.31% |
| 05-08 | Sprint Bioscience AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 02-14 | Sprint Bioscience AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Redeye comments on Sprint Bioscience’s Q4 2022 report, and we judge that the company is closing in on a licensing deal for its VADA project H1 2023e after some setbacks in recent months. We tweak our estimates and valuation.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/
© Modular Finance, source
| 1st Jan change | Capi. | |
|---|---|---|
| -19.31% | 8.61M | |
| +18.77% | 125B | |
| +14.05% | 108B | |
| -7.16% | 24.21B | |
| +2.07% | 22.78B | |
| -10.79% | 17.96B | |
| -41.74% | 16.43B | |
| -13.47% | 16.37B | |
| +2.23% | 13.58B | |
| +27.13% | 11.66B |
SPRINT BIOSCIENCE AB 
